Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
22.83
+0.10 (0.44%)
Feb 11, 2026, 4:00 PM EST - Market closed
Zymeworks Revenue
Zymeworks had revenue of $27.61M in the quarter ending September 30, 2025, with 72.59% growth. This brings the company's revenue in the last twelve months to $134.48M, up 116.21% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$134.48M
Revenue Growth
+116.21%
P/S Ratio
12.77
Revenue / Employee
$511,335
Employees
263
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 398.23M |
| Innoviva | 388.52M |
| Immunocore Holdings | 379.59M |
| MannKind | 313.79M |
| Vericel | 258.72M |
| Nurix Therapeutics | 83.98M |
| Tango Therapeutics | 66.50M |
| Precigen | 6.31M |
ZYME News
- 15 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - GlobeNewsWire
- 4 weeks ago - HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth - Seeking Alpha
- 4 weeks ago - Zymeworks Outlines Strategic Priorities and Outlook for 2026 - GlobeNewsWire
- 5 weeks ago - Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewsWire
- 2 months ago - Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Zymeworks Announces Participation in Upcoming Conferences - GlobeNewsWire